- Home
- /
- Treatment
- /
- Page 17
Treatments
The following database contains products that have been granted orphan status, or have been market approval in the EU or the USA.
You can filter the content by clicking on the titles: Product, Indication, Sponsor and Date. Clicking once, will filter the column alphabetically from A – Z and a second click on the same title will filter from Z – A.
Become a Partner.
Country | Product | Indication | Sponsor | Date |
---|---|---|---|---|
Tauroursodeoxycholic acid | Amyotrophic lateral sclerosis | Bruschettini s.r.l. | February 27, 2017 | |
Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene | Hunter Syndrome | Sangamo Therapeutics, Inc.;Point Richmond Tech Center, 501 Canal Boulevard;Richmond, California, 94804 | February 27, 2017 | |
1-(2,2-difluoro-2H-1,3-benzodioxol-5-yl)-N-{1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl}cyclopropane-1-carboxamide and ivacaftor | Cystic fibrosis | Vertex Pharmaceuticals (Europe) Limited | February 27, 2017 | |
Recombinant human histidyl-tRNA synthetase | Limb-girdle muscular dystrophy | aTyr Pharma;3545 John Hopkins Court, Suite 250;San Diego, California, 92121 | February 23, 2017 | |
6′-((6-aminopyrimidin-4-yl)amino)-8′-methyl-2’H-spiro[cyclohexane-1,3′-imidazo[1,5a]pyridine]-1′,5′-dione hydrochloride | Diffuse Large B-cell Lymphoma | eFFECTOR Therapeutics;11180 Roselle Street, Suite A;San Diego, California, 92121 | February 23, 2017 | |
Sofosbuvir/velpatasvir | Pediatric chronic hepatitis C virus (HCV) infection | Gilead Sciences, Inc.;333 Lakeside Drive;Foster City, California, 94404 | February 22, 2017 | |
Abatacept | Giant cell arteritis | Bristol-Myers Squibb Research & Development;Marketed Products Development - Regulatory Strategy, P.O. Box 5326;Princeton, New Jersey, 08543 | February 22, 2017 | |
Ustekinumab | Ulcerative colitis | Janssen Biotech, Inc.;1400 McKean Road;Spring House, Pennsylvania, 19477 | February 22, 2017 | |
Abatacept | Idiopathic inflammatory myopathy (IIM) | Bristol-Myers Squibb Research & Development;Marketed Products Development - Regulatory Strategy, P.O. Box 5326;Princeton, New Jersey, 08543 | February 22, 2017 | |
5-aza-2′-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one | Thalassemia | EpiDestiny Inc.;7536 Royal Portrush Drive;Solon, Ohio, 44139 | February 16, 2017 | |
6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate | Diffuse Large B-cell Lymphoma | Millennium Pharmaceuticals, Inc.;40 Landsdowne Street;Cambridge, Massachusetts, 02139 | February 14, 2017 | |
Dextromethorphan hydrobromide/quinidine sulfate | Amyotrophic lateral sclerosis | Avanir Pharmaceuticals;30 Enterprise, Suite 400;Aliso Viejo, California, 92656 | February 14, 2017 | |
EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody | Glioblastoma | EnGeneIC Ltd;25 Sirius Road, Building 2;Lane Cove West | February 14, 2017 | |
Nelfinavir | Multiple myeloma | Swiss Group for Clinical Cancer Research (SAKK);Effingerstrasse 33;Bern | February 14, 2017 | |
Glucopyranosyl lipid A stable emulsion | Follicular lymphoma | Immune Design Corp.;1616 Eastlake Ave. E, Suite 310;Seattle, Washington, 98102 | February 14, 2017 | |
Melatonin | Short bowel syndrome | Therapicon SrL;21 Via Malachia Marchesi de Taddei;Milano | February 14, 2017 | |
Atezolizumab | Metastatic Melanoma | Genentech, Inc.;1 DNA Way, MS 35-5E;South San Francisco, California, 94080 | February 13, 2017 | |
Atezolizumab | Metastatic Melanoma | Genentech, Inc.;1 DNA Way, MS 35-5E;South San Francisco, California, 94080 | February 13, 2017 | |
Sirolimus | Tuberous sclerosis | Aucta Pharmaceuticals, LLC;675 US Highway One;North Brunswick, New Jersey, 08902 | February 13, 2017 | |
(3’R,4’S,5’R)-N-[(3R,6S)-6-Carbamoyltetrahydro-2H-pyran-3-yl]-6”-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2”-oxo-1”,2”-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3”-indole]-5′-carboxamide mono(4-methylbenzenesulfonate) monohydrate | Liposarcoma | Daiichi Sankyo, Inc.;399 Thornall Street;Edison, New Jersey, 08837 | February 13, 2017 | |
N-[(2S)-5-{[(2S)-2-(4-fluorophenyl)cyclopropyl]amino}-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide bis-tosylate salt | Acute myeloid leukemia | Imago BioSciences, Inc.;2729 Debbie Court;San Carlos, California, 94070 | February 7, 2017 | |
Copanlisib | Nodal marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 | |
Modified cholera toxin | Gaucher disease | ERAD Therapeutics, Inc.;11500 Dahlia Terrace;Potomac, Maryland, 20854 | February 7, 2017 | |
Copanlisib | Splenic marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 | |
Copanlisib | Extranodal marginal zone lymphoma | Bayer HealthCare Pharmaceuticals, Inc.;100 Bayer Boulevard, P. O. Box 915;Hanover, New Jersey, 07981 | February 7, 2017 |